1 Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from defects in insulin secretion, insulin action, or both. It affects hundreds of millions globally, with type 2 diabetes mellitus (T2DM) being the most prevalent form, accounting for approximately 90~95% of all cases. Managing diabetes involves lifestyle interventions, oral antidiabetic drugs (OADs), and insulin therapy. However, despite the availability of numerous therapies, challenges persist, particularly in achieving optimal glycemic control and preventing long-term complications. Current treatments may lead to side effects such as weight gain, hypoglycemia, and cardiovascular risks, which complicate management strategies (Ahuja and Chou, 2016). Moreover, the heterogeneity of the disease requires personalized treatment regimens, and many patients fail to maintain long-term control, leading to the progression of microvascular and macrovascular complications (Salmen et al., 2023a).

The limitations of current therapies, including adverse effects and inadequate long-term control, underscore the urgent need for novel antidiabetic drugs that can provide better glycemic control, minimize side effects, and reduce the risk of complications such as cardiovascular disease. Emerging drug classes, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors, have shown promise in addressing some of these issues by offering improved glycemic control with additional benefits like weight loss and cardiovascular protection (Kaku et al., 2014). Additionally, these novel agents are associated with a lower risk of hypoglycemia compared to traditional therapies like sulfonylureas, making them attractive alternatives (Salmen et al., 2023a).

This study evaluates the clinical efficacy and safety of novel antidiabetic drugs, as well as their potential to improve glycemic control while minimizing side effects. The research provides evidence of the comparative effectiveness of these new therapies in real-world applications and clinical trials. It aims to offer guidance for clinicians in selecting appropriate treatment plans tailored to individual patient needs, thereby improving long-term outcomes and reducing the burden of diabetes-related complications. Specifically, this study will focus on assessing the performance of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, evaluating their impact on glycemic control, weight management, and cardiovascular health.

2 Classification and Mechanisms of Novel Antidiabetic Drugs

2.1 SGLT2 inhibitors: mechanism and clinical benefits

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of antidiabetic drugs that lower blood glucose levels by promoting glucose excretion through the kidneys. They act on the proximal tubules of the kidney, blocking glucose reabsorption and increasing urinary glucose excretion. This mechanism is independent of insulin, which makes SGLT2 inhibitors useful at any stage of type 2 diabetes management, particularly for patients with insulin resistance or β-cell dysfunction. Clinical benefits of SGLT2 inhibitors include improved glycemic control, weight reduction, and lowered blood pressure. Furthermore, SGLT2 inhibitors have demonstrated cardiovascular benefits, particularly in reducing the risk of hospitalization for heart failure and cardiovascular mortality (Xie et al., 2020). These drugs are also associated with renoprotective effects, showing a reduced risk of adverse kidney outcomes, such as end-stage kidney disease (DeFronzo, 2017; Xie et al., 2020).

2.2 GLP-1 receptor agonists: Mechanism and clinical benefits

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous incretin hormone GLP-1, which enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. These effects contribute to improved glycemic control and significant weight loss. GLP-1 receptor agonists are also associated with a lower risk of hypoglycemia due to their glucose-dependent mechanism of action. Additionally, recent studies have highlighted the cardiovascular benefits of GLP-1 receptor agonists, particularly in reducing the risk of stroke and cardiovascular events in patients with type 2 diabetes. They have shown significant reductions in major adverse cardiovascular events (MACE), making them a favorable option for patients with both diabetes and cardiovascular disease (Tomlinson et al., 2016; DeFronzo, 2017).

2.3 DPP-4 inhibitors and other emerging therapies

Dipeptidyl peptidase-4 (DPP-4) inhibitors work by inhibiting the enzyme DPP-4, which breaks down incretin hormones such as GLP-1. By preventing the degradation of GLP-1, DPP-4 inhibitors prolong the action of endogenous incretin hormones, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. DPP-4 inhibitors are generally well-tolerated, with a low risk of hypoglycemia and neutral effects on weight. However, unlike SGLT2 inhibitors and GLP-1 receptor agonists, DPP-4 inhibitors have not consistently shown cardiovascular or renal benefits, making them a less preferred option for patients at high cardiovascular risk. Emerging therapies, including dual and triple agonists targeting both incretin and other metabolic pathways, are under investigation to provide more comprehensive metabolic control. These novel agents aim to further improve glycemic control and reduce the risks of complications associated with type 2 diabetes (Luo, 2024).

3 Clinical Trials and Efficacy Data

3.1 Major clinical trials for SGLT2 inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been evaluated in several major clinical trials demonstrating their efficacy in glycemic control and cardiovascular outcomes. In a network meta-analysis comparing SGLT2 inhibitors with other antidiabetic drugs, it was found that these inhibitors significantly reduced myocardial infarction (RR 0.86) compared to control, with notable benefits for patients at high cardiovascular risk. Additionally, the combination of SGLT2 inhibitors and GLP-1 receptor agonists was shown to significantly reduce fasting plasma glucose and glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes, while also providing a reduction in body weight and systolic blood pressure (Guo et al., 2019). Another trial highlighted the protective effects of SGLT2 inhibitors in reducing renal outcomes and the risk of kidney disease progression (Cao et al., 2022).

3.2 Major clinical trials for GLP-1 receptor agonists

GLP-1 receptor agonists have been extensively studied for their glycemic and cardiovascular benefits. In a network meta-analysis, GLP-1 receptor agonists, such as liraglutide and semaglutide, significantly reduced major adverse cardiovascular events (MACE) in patients with type 2 diabetes, with liraglutide demonstrating reductions in cardiovascular mortality (Roddick and Zheng, 2018). Moreover, the SUSTAIN 9 trial confirmed that semaglutide, when added to SGLT2 inhibitor therapy, provided greater glycemic control and weight loss compared to placebo in patients with poorly controlled diabetes (Zinman et al., 2019).

3.3 Comparative efficacy of novel antidiabetic drugs

The comparative efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors has been explored in multiple meta-analyses. A systematic review of 98 clinical trials revealed that GLP-1 receptor agonists were most effective in reducing composite renal events, while SGLT2 inhibitors provided a lower risk of acute kidney injury compared to both DPP-4 inhibitors and GLP-1 receptor agonists (Yang et al., 2022). Furthermore, a comparative study found that SGLT2 inhibitors were more effective in reducing heart failure hospitalizations, while GLP-1 receptor agonists were superior in reducing stroke risk (Sabouret et al., 2022).

4 Safety and Adverse Effects

4.1 Common side effects of SGLT2 inhibitors

SGLT2 inhibitors are associated with several common side effects, primarily due to their mechanism of promoting glucose excretion through urine. One of the most notable adverse effects is an increased risk of urinary tract infections (UTIs) and genital infections, especially in women. These infections occur due to the increased glucose concentration in the urine, which creates an environment conducive to bacterial and fungal growth (Consoli et al., 2018). Another significant risk is diabetic ketoacidosis (DKA), particularly in individuals with type 1 diabetes or those with severe insulin deficiency. SGLT2 inhibitors can also lead to volume depletion and hypotension, especially in older adults or patients on diuretics (Edwards et al., 2022).

4.2 Safety profile of GLP-1 receptor agonists

GLP-1 receptor agonists are generally well-tolerated but can lead to gastrointestinal side effects, such as nausea, vomiting, and diarrhea, particularly when treatment is first initiated. These effects tend to be dose-dependent and may subside over time. Another concern is the potential for pancreatitis, although the incidence is relatively low. GLP-1 receptor agonists have also been associated with a low risk of hypoglycemia, particularly when used in combination with insulin or sulfonylureas (Consoli et al., 2018). Cardiovascular safety trials have demonstrated the beneficial effects of GLP-1 receptor agonists on cardiovascular outcomes, adding a favorable aspect to their safety profile (Wright et al., 2022).

4.3 Managing adverse effects in clinical practice

Managing the adverse effects of novel antidiabetic therapies involves patient education and regular monitoring. For SGLT2 inhibitors, it is important to advise patients to maintain proper hydration to mitigate the risks of hypotension and volume depletion. Monitoring for signs of infection and educating patients on proper hygiene can help reduce the risk of urinary tract and genital infections. Clinicians should be vigilant about the risk of diabetic ketoacidosis, particularly in patients with type 1 diabetes, and discontinue therapy if ketoacidosis develops (Edwards et al., 2022). For GLP-1 receptor agonists, starting at a low dose and gradually increasing the dose can help minimize gastrointestinal side effects. Regular monitoring for pancreatitis symptoms and avoiding the combination with other medications that increase pancreatitis risk is also recommended.

5 Long-Term Outcomes and Cardiovascular Benefits

5.1 Impact of SGLT2 inhibitors on cardiovascular outcomes

SGLT2 inhibitors have demonstrated significant cardiovascular benefits in patients with type 2 diabetes. Clinical trials such as the CANVAS and EMPA-REG OUTCOME trials have shown a reduction in the risk of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. Moreover, these drugs have been particularly effective in reducing hospitalization for heart failure (Zelniker et al., 2019). The benefits appear to be independent of glucose control, with mechanisms likely related to hemodynamic effects, such as reducing blood pressure and promoting diuresis (Kim et al., 2021). SGLT2 inhibitors have also shown renoprotective effects, slowing the progression of chronic kidney disease in patients with diabetes (Scheen, 2018).

5.2 Cardiovascular and renal benefits of GLP-1 receptor agonists

GLP-1 receptor agonists have also shown significant cardiovascular benefits, primarily in reducing MACE, particularly in patients with established atherosclerotic cardiovascular disease. The LEADER and SUSTAIN trials demonstrated the ability of GLP-1 receptor agonists, such as liraglutide and semaglutide, to reduce the risk of cardiovascular death and stroke (Song et al., 2024). GLP-1 receptor agonists exert their benefits through anti-atherogenic and anti-inflammatory mechanisms, independent of their glucose-lowering effects. In addition to cardiovascular protection, these drugs have shown modest renoprotective effects, particularly in reducing the progression of albuminuria (Ahuja and Chou, 2016; Salmen et al., 2023b).

5.3 Long-term efficacy and safety in diabetic patients

The long-term efficacy and safety of SGLT2 inhibitors and GLP-1 receptor agonists have been widely supported by cardiovascular outcomes trials (CVOTs). Both classes of drugs offer complementary benefits: SGLT2 inhibitors are more effective in preventing heart failure and renal outcomes, while GLP-1 receptor agonists have a more pronounced effect on reducing atherosclerotic events. When combined, these therapies provide additional protection, as evidenced in recent real-world studies, which show that their combination reduces cardiovascular risks more effectively than either agent alone (Azoulay et al., 2023). Despite these benefits, long-term safety considerations, such as the increased risk of urinary tract infections with SGLT2 inhibitors and gastrointestinal issues with GLP-1 receptor agonists, should be managed carefully in clinical practice (Edwards et al., 2022).

6 Comparative Effectiveness of Novel Antidiabetic Drugs

6.1 Comparison of SGLT2 inhibitors and GLP-1 receptor agonists

SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated efficacy in both glycemic control and cardiovascular benefits. A 2021 meta-analysis comparing these two drug classes found that SGLT2 inhibitors were more effective at reducing the risk of hospitalization for heart failure, while GLP-1 receptor agonists were superior in reducing the risk of non-fatal stroke (Palmer et al., 2021). Both classes significantly reduced all-cause mortality, but SGLT2 inhibitors provided more pronounced renal protection, particularly in patients with chronic kidney disease, whereas GLP-1 receptor agonists had a stronger effect on lowering non-fatal cardiovascular events such as myocardial infarction and stroke (Wright et al., 2022).

6.2 Combined use of novel antidiabetic drugs

The combination of SGLT2 inhibitors and GLP-1 receptor agonists has shown significant clinical promise. Studies indicate that the combination therapy leads to greater reductions in HbA1c, body weight, and blood pressure compared to either drug used alone (Díaz-Trastoy et al., 2020). Real-world data also suggest that this combination therapy is associated with a decreased risk of major adverse cardiovascular events (MACE) and hospitalization for heart failure, providing additional cardiovascular benefits beyond what either drug achieves independently (Azoulay et al., 2023). Additionally, a systematic review highlighted that the combination therapy resulted in better renal outcomes, with reduced progression of albuminuria and estimated glomerular filtration rate (GFR) decline (Guo et al., 2020).

6.3 Patient-centric considerations in drug selection

The choice between SGLT2 inhibitors and GLP-1 receptor agonists, or their combination, should be driven by individual patient profiles. For patients at higher risk of heart failure or chronic kidney disease, SGLT2 inhibitors may be preferred due to their stronger protective effects in these areas. Conversely, for patients with a history of stroke or atherosclerotic cardiovascular disease, GLP-1 receptor agonists may offer more benefit. Combination therapy should be considered in patients who fail to achieve adequate glycemic control with monotherapy and those who have multiple comorbidities, such as heart failure and cardiovascular disease, to maximize cardiovascular and renal protection (Azoulay et al., 2023).

7 Cost-Effectiveness and Accessibility

7.1 Economic evaluation of novel antidiabetic drugs

Recent studies on the cost-effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists suggest that these drugs, despite their higher initial cost, provide long-term cost savings by reducing the incidence of diabetes-related complications, such as cardiovascular and renal events. newer antidiabetic medications, including SGLT2 inhibitors and GLP-1 receptor agonists, are cost-effective compared to traditional therapies like insulin or sulfonylureas, primarily due to their ability to prevent costly complications. A U.S.-based study indicated that adding SGLT2 inhibitors to dual therapy with metformin and DPP-4 inhibitors could improve survival and quality-adjusted life-years (QALYs) while being associated with cost savings of $9,511 per patient over a lifetime (Pawaskar et al., 2021).

7.2 Accessibility in low and middle-income countries

Access to newer antidiabetic drugs in low and middle-income countries (LMICs) remains a significant challenge due to their high cost and limited inclusion in national formularies. A study published in The Lancet evaluated the price targets for SGLT2 inhibitors and GLP-1 receptor agonists to make them cost-effective in LMICs. The study found that, to achieve cost-effectiveness, SGLT2 inhibitors would need to be priced at $224 per person per year, while GLP-1 receptor agonists would require a price of $208 per person per year (Rothenberger et al., 2021). These targets represent significant reductions from current prices and highlight the need for global initiatives to lower drug prices in LMICs.

7.3 Strategies to improve drug affordability

To improve the affordability of novel antidiabetic drugs, especially in LMICs, several strategies have been proposed. These include negotiating lower drug prices through bulk purchasing agreements, promoting the local production of generics, and advocating for the inclusion of these drugs in national essential medicines lists (Tonelli and Straus, 2022). Expanding the use of value-based pricing models, where drug prices are tied to their demonstrated clinical benefits, is another approach that could help make these drugs more accessible. Additionally, initiatives like the Clinton Health Access Initiative have focused on reducing the prices of essential medicines, including SGLT2 inhibitors, in LMICs, potentially making these drugs more affordable and widely available (Rothenberger et al., 2021).

8 Future Directions in Antidiabetic Drug Development

8.1 Next-generation antidiabetic drugs

The development of next-generation antidiabetic drugs focuses on designing agents with improved efficacy, reduced side effects, and more targeted mechanisms of action. One promising area involves the development of "smart" insulin analogs that can automatically adjust insulin delivery based on blood glucose levels, thereby minimizing the risk of hypoglycemia. These glucose-responsive analogs could revolutionize diabetes management by offering a more precise and physiological control of blood glucose (Jarosinski et al., 2021). Another direction is the creation of combination therapies that exploit different mechanisms of action, such as combining insulin analogs with GLP-1 receptor agonists, or SGLT2 inhibitors, to provide both glycemic control and cardiovascular protection (Levina and Lay, 2020).

8.2 Personalized medicine in diabetes management

Personalized medicine is transforming diabetes care by allowing for more tailored treatment approaches based on an individual's genetic makeup, environmental factors, and lifestyle. The emerging field of pharmacogenomics is particularly important, as it allows clinicians to predict how a patient will respond to specific glucose-lowering medications, thereby optimizing drug efficacy and reducing the risk of adverse effects (Scheen, 2016). Advances in next-generation sequencing (NGS) and biomarkers will likely allow for even more personalized treatment strategies, enabling clinicians to adjust treatments based on genetic variations that influence drug metabolism and response (Linsley et al., 2021).

8.3 Integration of antidiabetic drugs with digital health solutions

The integration of antidiabetic drugs with digital health solutions is a key trend in future diabetes care. Digital health platforms can provide real-time data on glucose levels, medication adherence, and lifestyle factors, allowing for more precise adjustments in therapy. Personalized drug delivery systems, which adapt dosage and timing based on patient-specific data collected through digital health platforms, are becoming a reality (Raijada et al., 2021). Additionally, the use of artificial intelligence (AI) in analyzing large datasets from continuous glucose monitors and other wearable devices can help predict blood glucose trends and recommend timely interventions, further improving patient outcomes.

9 Concluding Remarks

The development of novel antidiabetic drugs such as SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors has significantly advanced the management of type 2 diabetes. These drugs not only improve glycemic control but also offer cardiovascular and renal protection. SGLT2 inhibitors are particularly effective in reducing the risk of heart failure and kidney disease progression, while GLP-1 receptor agonists excel in reducing major adverse cardiovascular events such as myocardial infarction and stroke. Additionally, combination therapies involving these novel agents have shown superior outcomes in both glycemic control and reducing cardiovascular risks compared to monotherapies.

The availability of these novel antidiabetic drugs has reshaped treatment algorithms, particularly for patients with comorbid conditions such as cardiovascular disease and chronic kidney disease. The emerging data suggest that a more personalized approach, tailoring drug selection to individual patient profiles, will optimize outcomes. Furthermore, the continued development of fixed-dose combination therapies and "smart" insulin analogs will likely enhance patient adherence and improve clinical outcomes. The integration of pharmacogenomics and precision medicine will further enhance the effectiveness of treatment by addressing inter-individual variability in drug responses.

Future research should focus on long-term outcomes and head-to-head comparisons of these novel drug classes to determine the most effective treatment combinations. Studies exploring the role of pharmacogenomics in predicting patient responses to antidiabetic drugs will be crucial in advancing personalized medicine in diabetes care. Additionally, research should continue exploring the integration of antidiabetic therapies with digital health solutions to improve treatment adherence and patient outcomes. Finally, further efforts are needed to enhance the affordability and accessibility of these drugs in low- and middle-income countries.

Acknowledgments

I thank the anonymous peer reviewers for their valuable comments and feedback.

Conflict of Interest Disclosure

The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Ahuja V., and Chou C., 2016, Novel therapeutics for diabetes: uptake, usage trends, and comparative effectiveness, Current Diabetes Reports, 16(6): 47.

https://doi.org/10.1007/s11892-016-0744-4

PMID: 27076180

Azoulay L., Simms-Williams N., Yin H., Lu S., Treves N., and Yu O.H., 2023, The combined use of SGLT2 inhibitors and GLP-1 receptor agonists on the risk of cardiovascular events among patients with type 2 diabetes, Diabetes, 72(Supplement_1): 268-OR

https://doi.org/10.2337/db23-268-or

Cao H., Liu T., Wang L., and Ji Q., 2022, Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: a systematic review and network meta-analysis, Diabetes, Obesity and Metabolism, 24: 1448-1457.

https://doi.org/10.1111/dom.14702

PMID: 35665989 PMCID: PMC9541855

Consoli A., Formoso G., Baldassarre M.D., and Febo F., 2018, A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment, Expert Opinion on Drug Safety: 17: 293-302.

https://doi.org/10.1080/14740338.2018.1428305

PMID: 29334278

DeFronzo R., 2017, Combination therapy with GLP‐₁ receptor agonist and SGLT2 inhibitor, Diabetes, 19: 1-10.

https://doi.org/10.1111/dom.12982

PMID: 28432726 PMCID: PMC5643008

Díaz-Trastoy O., Villar-Taibo R., Sifontes-Dubón M., Mozo-Peñalver H., Bernabeu-Morón I., Cabezas-Agrícola J.M., Muñoz-Leira V., Peinó-García R., Martís-Sueiro A., García-López J.M., and Martínez-Olmos M.A., 2020, GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-life clinical practice, Clinical Therapeutics, 42(2): 1-12.

https://doi.org/10.1016/j.clinthera.2019.12.012

PMID: 32005534

Edwards K., Li X., and Lingvay I., 2022, Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study, The Journal of Clinical Endocrinology and Metabolism, 108(4): 920-930.

https://doi.org/10.1210/clinem/dgac618

PMID: 36268825

Guo M., Gu J., Li J., and Xu Y., 2019, 2300-PUB: the efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and meta-analysis, Diabetes, 67(2): 294-304.

https://doi.org/10.2337/DB19-2300-PUB

PMID: 31900793

Guo M., Gu J., Li J., and Xu Y., 2020, The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and meta-analysis, Endocrine, 67: 294-304.

https://doi.org/10.1007/s12020-019-02175-6

PMID: 31900793

Jarosinski M., Chen Y., Varas N., Dhayalan B., and Chatterjee D., 2021, New horizons: next-generation insulin analogs: structural principles and clinical goals, The Journal of Clinical Endocrinology and Metabolism, 107(4):909-928.

https://doi.org/10.1210/clinem/dgab849

PMID: 34850005 PMCID: PMC8947325

Kaku K., Watada H., Iwamoto Y., Utsunomiya K., Terauchi Y., Tobe K., Tanizawa Y., Araki E., Ueda M., Suganami H., and Watanabe D., 2014, Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus, Cardiovascular Diabetology, 13: 65-65.

https://doi.org/10.1186/1475-2840-13-65.

PMID: 24678906 PMCID: PMC4021346

Kim C.H., Hwang I., Ahn C.H., Yoon Y., and Cho G., 2021, Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus, International Journal of Cardiology, 364: 104-111.

https://doi.org/10.21203/rs.3.rs-734897/v1

PMID: 35716949

Levina A., and Lay P.A., 2020, Metal-based anti-diabetic drugs: advances and challenges, Dalton Transactions, 40(44): 11675-11686.

https://doi.org/10.1039/c1dt10380f

PMID: 21750828

Linsley P., Greenbaum C., and Nepom G., 2021, Uncovering pathways to personalized therapies in type 1 diabetes, Diabetes, 70(4): 831-841.

https://doi.org/10.2337/db20-1185

PMID: 33741606 PMCID: PMC7980192

Luo M.T., 2024, Unveiling the genetic heterogeneity of type 2 diabetes: from multi-ethnic studies to personalized medicine, Evidence, 14(1): 11-15.

https://doi.org/10.5376/be.2024.14.0002

Palmer S.C., Tendal B., Mustafa R.A., Vandvik P.O., Li S., Hao Q., Tunnicliffe D., Ruospo M., Natale P., Saglimbene V., Nicolucci A., Johnson D.W., Tonelli M., Rossi M. C., Badve S.V., Cho Y., Nadeau-Fredette A.C., Burke M., Faruque L.I., Lloyd A., Ahmad N., Liu Y., Tiv S., Millard T., Gagliardi L., Kolanu N., Barmanray R.D., McMorrow R., Cortez A.K.R., White H., Chen X., Zhou X., Liu J., Rodríguez A.F., González-Colmenero A.D., Wang Y., Li L., Sutanto S., Solis R.C., González-Colmenero F.D., Rodriguez-Gutierrez R., Walsh M., Guyatt G., Strippoli G.F.M., and Strippoli G.F.M., 2021, Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomized controlled trials, The BMJ, 372: m4573.

https://doi.org/10.1136/bmj.m4573

PMID: 33441402 PMCID: PMC7804890

Pawaskar M., Bilir S.P., Kowal S., Li Q., Weiss T., and Davies G., 2021, Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes, The American Journal of Managed Care, 27(8): e269-e277.

https://doi.org/10.37765/ajmc.2021.88728

PMID: 34460181

Raijada D.K., Wac K., Greisen E., Rantanen J., and Genina N., 2021, Integration of personalized drug delivery systems into digital health, Advanced Drug Delivery Reviews, 176: 113857.

https://doi.org/10.1016/j.addr.2021.113857

PMID: 34389172

Roddick A., and Zheng S., 2018, Comparative cardiovascular efficacy of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 agonists-a network meta-analysis, Diabetes, 67(Supplement_1):427-P

https://doi.org/10.2337/DB18-427-P

Rothenberger S.D., Gellad W.F., Luo J., Feldman R., and Mahtta D., 2021, Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: acost-effectiveness and price target analysis, The Lancet Diabetes and Endocrinology, 9(12): 825-836.

https://doi.org/10.1016/S2213-8587(21)00240-0

PMID: 34656210

Sabouret P., Bocchino P., Angelini F., D'Ascenzo F., Galati G., Fysekidis M., de Ferrari G.M., Fischman D.L., Bhatt D.L., and Biondi-Zoccai G., 2022, Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis, Minerva Cardiology and Angiology, 71(2): 199-207.

https://doi.org/10.23736/S2724-5683.22.05900-2

PMID: 35195376

Salmen T., Rizvi A., Rizzo M., Pietrosel V., Bica I., Diaconu C.T., Potcovaru C.G., Salmen B.M., Coman O., Bobircă A., Stoica R., and Stoian A.M.P., 2023a, Antidiabetic molecule efficacy in patients with type 2 diabetes mellitus-a real-life clinical practice study, Biomedicines, 11(9): 2455.

https://doi.org/10.3390/biomedicines11092455

PMID: 37760896 PMCID: PMC10525559

Salmen T., Serbanoiu L.I., Bica I.C., Serafinceanu C., Muzurović E.M., Janež A., Busnatu Ș., Banach M., Rizvi A., and Stoian A.M.P., 2023b, A critical view over the newest antidiabetic molecules in light of efficacy-a systematic review and meta-analysis, International Journal of Molecular Sciences, 24(11): 9760.

https://doi.org/10.3390/ijms24119760

PMID: 37298707 PMCID: PMC10253587

Scheen A., 2016, Precision medicine: the future in diabetes care?, Diabetes Research and Clinical Practice, 117: 12-21.

https://doi.org/10.1016/j.diabres.2016.04.033

PMID: 27329017

Scheen A., 2018, Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists, Diabetes Research and Clinical Practice, 143: 88-100.

https://doi.org/10.1016/j.diabres.2018.06.008

PMID: 29944969

Song R.S., Sun K., Wang Y.X., Liu S.K., and Bu Y.Y., 2024, Synthetic microbial communities: redesigning genetic pathways for enhanced functional synergy, Molecular Microbiology Research, 14(1): 39-48.

https://doi.org/10.5376/mmr.2024.14.0005.

Tomlinson B., Hu M., Zhang Y., Chan P., and Liu Z., 2016, An overview of new GLP-1 receptor agonists for type 2 diabetes, Expert Opinion on Investigational Drugs, 25: 145-158.

https://doi.org/10.1517/13543784.2016.1123249

PMID: 26587691

Tonelli M., and Straus S.E., 2022, Increasing societal benefit from cardiovascular drugs, Circulation, 146(21): 1627-1635.

https://doi.org/10.1161/CIRCULATIONAHA.122.059032

PMID: 36409780

Wright A., Carr M., Kontopantelis E., Leelarathna L., Thabit H., Emsley R., Buchan I., Mamas M.A., van Staa T.P., Sattar N., Ashcroft D.M., and Rutter M.K., 2022, Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes, Diabetes Care, 45(4): 909-918.

https://doi.org/10.2337/dc21-1113

PMID: 35100355

Xie Y., Bowe B., Gibson A.K., McGill J.B., Maddukuri G., Yan Y., and Al‐Aly Z., 2020, Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases, Diabetes Care, 43: 2859-2869.

https://doi.org/10.2337/dc20-1890

Yang S., He W., Zhao L., and Mi Y., 2022, Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis, PLoS ONE, 17: 0267025.

https://doi.org/10.1371/journal.pone.0267025

PMID: 35421174 PMCID: PMC9009659

Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M., Bonaca M.P., Mosenzon O., Kato E.T.,. Cahn A, Bhatt D.L., Leiter L.A., McGuire D.K., Wilding J.P.H., and Sabatine M.S., 2019, Comparison of the effects of GLP-1 receptor agonists and SGLT2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus, Circulation, 139: 2022-2031.

https://doi.org/10.1161/CIRCULATIONAHA.118.038868

PMID: 30786725

Zinman B., Bhosekar V., Busch R., Holst I., Ludvik B., Thielke D., et al., 2019, Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial, The Lancet Diabetes and Endocrinology, 7(5): 356-367.

https://doi.org/10.1016/S2213-8587(19)30066-X

PMID: 30833170